Page last updated: 2024-11-12

desmosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Desmosine: A rare amino acid found in elastin, formed by condensation of four molecules of lysine into a pyridinium ring. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID15942890
CHEBI ID37628
SCHEMBL ID62181
MeSH IDM0006081

Synonyms (18)

Synonym
pyridinium,4-[(4s)-4-amino-4-carboxybutyl]-1-[(5s)-5-amino-5-carboxypentyl]-3,5-bis[(3s)-3-amino-3-carboxypropyl]-
desmosine
CHEBI:37628
11003-57-9
4-[(4s)-4-amino-4-carboxybutyl]-1-[(5s)-5-amino-5-carboxypentyl]-3,5-bis[(3s)-3-amino-3-carboxypropyl]pyridinium
unii-4mol2j0tly
4mol2j0tly ,
pyridinium, 4-(4-amino-4-carboxybutyl)-1-(5-amino-5-carboxypentyl)-3,5-bis(3-amino-3-carboxypropyl)- (van)
pyridinium, 4-(4-amino-4-carboxybutyl)-1-(5-amino-5-carboxypentyl)-3,5-bis(3-amino-3-carboxypropyl)-
SCHEMBL62181
desmosine cation
6-(4-((4s)-4-amino-4-carboxybutyl)-3,5-bis((3s)-3-amino-3-carboxypropyl)-1-pyridiniumyl)-l-norleucine
desmosine, (+)-
4-(4-amino-4-carboxybutyl)-1-(5-amino-5-carboxypentyl)-3,5-bis(3-amino-3-carboxypropyl)pyridinium
Q61184
(2s)-2-amino-6-[4-[(4s)-4-amino-4-carboxybutyl]-3,5-bis[(3s)-3-amino-3-carboxypropyl]pyridin-1-ium-1-yl]hexanoic acid
DTXSID801106522
3,5-bis((s)-3-amino-3-carboxypropyl)-4-((s)-4-amino-4-carboxybutyl)-1-((s)-5-amino-5-carboxypentyl)pyridin-1-ium

Research Excerpts

Overview

Desmosine (DES) is an elastin-derived, cross-link amino acid. It is not metabolized; hence, its urinary levels reflect Elastin breakdown.

ExcerptReferenceRelevance
"Desmosine is a stable breakdown product of elastin that can be reliably measured in urine samples. "( Higher urine desmosine levels are associated with mortality in patients with acute lung injury.
Church, GD; Eisner, MD; Hayden, DL; Matthay, MA; McClintock, DE; Starcher, B; Thompson, BT, 2006
)
2.15
"Desmosine is a cross-link amino acid unique to elastin. "( Desmosine radioimmunoassay for measuring elastin degradation in vivo.
Bergofsky, EH; Harel, S; Hurewitz, A; Janoff, A; Yu, SY, 1980
)
3.15
"Desmosine (DES) is an elastin-derived, cross-link amino acid, which is not metabolized; hence, its urinary levels reflect elastin breakdown. "( Urinary desmosine excretion in acute exacerbations of COPD: a preliminary report.
Baccheschi, J; Fiorenza, D; Iadarola, R; Luisetti, M; Lupi, A; Snider, GL; Tinelli, C; Trisolini, R; Viglio, S, 2002
)
2.19
"Desmosine is an amino acid specific to elastin. "( Urinary desmosine, elastolysis, and lung disease.
Cooke, NT; Guz, A; Hutchison, DC; Pai, V; Phillips, GJ; Tetley, TD, 1991
)
2.16

Effects

ExcerptReferenceRelevance
"Desmosine has been quantitated in the normally grown fetal and early infant lung by radioimmunoassay. "( Assessment of elastin maturation by radioimmunoassay of desmosine in the developing human lung.
Aber, V; Desai, R; Wigglesworth, JS, 1988
)
1.96

Toxicity

ExcerptReferenceRelevance
" In a 2-week, randomized, double-blind trial, 8 patients receiving 150 kDa HA (mean molecular weight) and 3 others given placebo did not show significant adverse effects with regard to spirometry, electrocardiograms, and hematological indices."( A pilot clinical trial to determine the safety and efficacy of aerosolized hyaluronan as a treatment for COPD.
Cantor, J; Ma, S; Turino, G, 2017
)
0.46

Pharmacokinetics

ExcerptReferenceRelevance
" The biological half-life (t 1/2 beta) of desmosine varied between 81-489 min."( Pharmacokinetics of intravenously administered desmosine in sheep.
Hoyt, RF; Jackson, AJ; Phillips, YY; Verma, PS, 1984
)
0.79

Compound-Compound Interactions

ExcerptReferenceRelevance
"This study aimed to explore whether and how anti-lysyl oxidase (anti-LOX) combined with a vacuum device (VD) could promote penile lengthening and to evaluate the effect on erectile function."( Anti-lysyl oxidase combined with a vacuum device induces penile lengthening by remodeling the tunica albuginea.
Fu, FD; Li, T; Qin, F; Wang, R; Wu, CJ; Yuan, JH,
)
0.13

Dosage Studied

ExcerptRelevanceReference
" To test this theory we examined the antiproteolytic activity of A1AT exposed to quartz in vitro and found that it was decreased in a dose-response fashion."( Mechanisms of mineral dust-induced emphysema.
Churg, A; Li, K; Zay, K, 1997
)
0.3
"AZD1236 dosed orally at 75 mg twice daily was generally well tolerated over 6 weeks in patients with moderate-to-severe COPD."( Effects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: a randomised controlled trial.
Dahl, R; Holt, A; Lindqvist, A; Mo, J; Samuelsson, V; Titlestad, I; Wang, M; Wielders, P; Wray, H, 2012
)
0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic amino acidAn amino acid whose structure includes an aromatic ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (417)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990171 (41.01)18.7374
1990's79 (18.94)18.2507
2000's76 (18.23)29.6817
2010's81 (19.42)24.3611
2020's10 (2.40)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.60 (24.57)
Research Supply Index6.09 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index66.41 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials11 (2.56%)5.53%
Reviews15 (3.49%)6.00%
Case Studies2 (0.47%)4.05%
Observational1 (0.23%)0.25%
Other401 (93.26%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]